At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
PrEP-001 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase IIa, Randomised, Double-blind, Placebo-controlled Outpatients Study to Investigate the Duration of Effect and Safety of PrEP-001 Given Prophylactically in Healthy Subjects, Subsequently Challenged With Human Rhinovirus (HRV-16)
In Brief
A Phase 2 clinical trial evaluating PrEP-001 and Placebo for Viral Upper Respiratory Tract Infection. Completed, enrolled 102 participants across 1 site.
Detailed Summary
A study to examine the duration of effect of PrEP-001 in healthy subjects challenged with HRV-16
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsViral Upper Respiratory Tract Infection
CountriesUnited Kingdom
CollaboratorsHvivo
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2016
Primary CompletionSep 2016
First PostedNov 2017
TodayJul 2026
First PostedNov 9, 2017
Enrollment StartApr 6, 2016
Primary CompletionSep 30, 2016
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.6 years ago
Interventions
PrEP-001drug
Placeboother